Company intelligence / Profile preview

Instituto Grifols

Parets del Vallès, Barcelona, Spain

Ownership: Private
Employees: ~23800
Development stage: Other

Overview

Instituto Grifols is a major global producer of plasma-derived medicines with a strong commercial portfolio including Xembify, Prolastin-C, and Gamunex. Its clinical pipeline is robust, featuring Phase 3 programs for albumin in liver cirrhosis (PRECIOSA) and fibrinogen for surgical bleeding, along with early-stage recombinant programs via its GigaGen subsidiary.

Therapeutic areas: HematologyImmunologyCardiovascularNeurologyRare DiseasesGastroenterologyOncologyOphthalmology
Modalities: BiologicPlasma-derived proteinsRecombinant proteinMonoclonal antibodySmall moleculeDevice
Industry: Biotech

Drug pipeline

1 asset

convalescent anti-SARS-CoV-2 MBT plasma

Partnerships

SelagineOliX PharmaceuticalsMondragon Corporation

Beyond the preview

Go deeper on Instituto Grifols.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Instituto Grifols.

Explore the full profile